Announcements
- Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
- Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
- Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
More ▼
Key statistics
As of last trade Perspective Therapeutics Inc (AAJ0:MUN) traded at 11.60, -32.56% below its 52-week high of 17.20, set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 11.60 |
Average volume | 87.05 |
---|---|
Shares outstanding | 67.38m |
Free float | 53.61m |
P/E (TTM) | -- |
Market cap | 643.46m USD |
EPS (TTM) | -1.62 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:04 BST.
More ▼